GlassScriptPhysician profile
Makayla Kiser
NPI 1023456878
$8,586.50
in general payments reported to CMS, 2019-2025
53 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $912 · 2021: $1,324 · 2022: $1,198 · 2023: $1,449 · 2024: $1,548 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,328.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,130.43 | 2021-2025 | |
| Novo Nordisk INC | $1,045.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $794.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $563.89 | 2019-2025 | |
| Lilly USA, LLC | $532.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $475.98 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.59 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $391.20 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.06 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $232.37 | 2021-2025 | |
| Astellas Pharma US INC | $223.16 | 2019-2024 | Veozah |
| Amgen INC. | $218.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $203.69 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $184.67 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $182.27 | 2023-2025 | Auvelity, Sunosi |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Makayla Kiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.